title: The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance.
abstract: As part of its Medical Technologies Evaluation Programme (MTEP), the National Institute for Health and Care Excellence (NICE) invited Neotract (manufacturer) to submit clinical and economic evidence for their prostatic urethral lift device, Urolift, for the relief of lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS BPH). The Urolift System uses implants to retract the prostatic lobe away from the urethral lumen. The clinical evidence used in the manufacturer's submission shows that Urolift is effective for the treatment of BPH. Urolift delivers a weighted mean International Prostate Symptom Score (IPSS) improvement of between 9.22 and 11.82 points. These Urolift improvements are greater than a published 'marked improvement' in IPSS score of 8.80. Comparison with randomised controlled trials (RCTs) of TURP (Transurethral Resection of Prostate) and HoLEP (Holmium Laser Enucleation of Prostate) show that Urolift does not yield better clinical outcomes from baseline compared to TURP and HoLEP in terms of IPSS, QoL (Quality of Life) and Qmax (maximum urinary flow). However, Urolift appears to have the advantage in terms of minimal and mild complications, and this may be of interest to patients and urologists. The economic case for Urolift was made using a very detailed and thorough de novo cost model. The base case posed by the manufacturer placed Urolift at almost cost-neutral (£3 cost incurring, based on 2014 prices) compared to TURP, and £418 cost incurring compared to HoLEP. In an additional scenario comparing day-case Urolift with in-patient TURP, the estimated per-patient savings with Urolift were £286 compared with monopolar TURP (mTURP) and £159 compared with bipolar TURP (BiTURP). NICE guidance MTG26 recommends that the case for adoption of Urolift was supported by the evidence, when implemented in a day-case setting.
authors.affiliation: Cardiff University, Cardiff, Wales, UK. alistair.ray@wales.nhs.uk.
authors.forename: Alistair
authors.initials: A
authors.lastname: Ray
authors.affiliation: Cardiff University, Cardiff, Wales, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Morgan
authors.affiliation: Cardiff and Vale University Health Board, Cardiff, Wales, UK.
authors.forename: Antony
authors.initials: A
authors.lastname: Wilkes
authors.affiliation: National Institute for Health and Care Excellence, Manchester, UK.
authors.forename: Kimberley
authors.initials: K
authors.lastname: Carter
authors.affiliation: Cardiff and Vale University Health Board, Cardiff, Wales, UK.
authors.forename: Grace
authors.initials: G
authors.lastname: Carolan-Rees
mesh_terms: D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000209:etiology / Q000601:surgery*; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications*; D019736:Prostheses and Implants; D016896:Treatment Outcome; D014521:Urethra / Q000601:surgery
references.citation: J Urol. 2004 Nov;172(5 Pt 1):1926-9
references.pmid: 15540757
references.citation: Urol Pract. 2015 Jan;2(1):26-32
references.pmid: 37537806
references.citation: J Urol. 2013 Dec;190(6):2161-7
references.pmid: 23764081
references.citation: J Urol. 1999 Nov;162(5):1640-4
references.pmid: 10524887
references.citation: BJU Int. 2014 Apr;113(4):615-22
references.pmid: 24765680
references.citation: J Urol. 2015 Feb;193(2):570-8
references.pmid: 25219699
references.citation: Eur Urol. 2015 Oct;68(4):643-52
references.pmid: 25937539
references.citation: J Urol. 1995 Nov;154(5):1770-4
references.pmid: 7563343
references.citation: Can J Urol. 2010 Dec;17(6):5447-52
references.pmid: 21172109
references.citation: Transfus Med. 2003 Aug;13(4):205-18
references.pmid: 12880391
references.citation: J Urol. 2004 Sep;172(3):1012-6
references.pmid: 15311026
references.citation: Urol Int. 2009;82(2):130-5
references.pmid: 19321996
references.citation: Eur Urol. 2007 Nov;52(5):1456-63
references.pmid: 17499427
references.citation: Eur Urol. 2008 Apr;53(4):744-9
references.pmid: 17475395
references.citation: J Sex Med. 2012 Feb;9(2):568-75
references.pmid: 22172161
references.citation: BJU Int. 2006 Jan;97(1):85-9
references.pmid: 16336334
references.citation: Health Technol Assess. 2008 Nov;12(35):iii, ix-x, 1-146, 169-515
references.pmid: 19032882
references.citation: Arch Esp Urol. 2013 Jul-Aug;66(6):584-91
references.pmid: 23985459
references.citation: Int Urol Nephrol. 2014 Jul;46(7):1277-82
references.pmid: 24492988
references.citation: Eur Urol. 2015 Apr;67(4):704-13
references.pmid: 25466940
references.citation: PLoS One. 2014 Jul 08;9(7):e101615
references.pmid: 25003963
references.citation: Urology. 2012 Jan;79(1):5-11
references.pmid: 22202539
references.citation: J Sex Med. 2014 Jan;11(1):279-87
references.pmid: 24119101
references.citation: Appl Health Econ Health Policy. 2012 Sep 1;10(5):295-7
references.pmid: 22909081
references.citation: Prog Urol. 2012 Sep;22(10):590-7
references.pmid: 22920338
references.citation: J Urol. 2003 Oct;170(4 Pt 1):1270-4
references.pmid: 14501739